Acétate de cyprotérone : Questions médicales fréquentes
Nom anglais: Cyproterone Acetate
Descriptor UI:D017373
Tree Number:D04.210.500.883.419.150
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Acétate de cyprotérone : Questions médicales les plus fréquentes",
"headline": "Acétate de cyprotérone : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Acétate de cyprotérone : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-12",
"dateModified": "2025-01-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Acétate de cyprotérone"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cyprotérone",
"url": "https://recherchemedicale.com/mesh/D003534",
"about": {
"@type": "MedicalCondition",
"name": "Cyprotérone",
"code": {
"@type": "MedicalCode",
"code": "D003534",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.210.500.883.419"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Acétate de cyprotérone",
"alternateName": "Cyproterone Acetate",
"code": {
"@type": "MedicalCode",
"code": "D017373",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Thibault Passeri",
"url": "https://recherchemedicale.com/author/Thibault%20Passeri",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurosurgery, Hôpital Lariboisière, Paris VII-Diderot University, 2 rue Ambroise Pare, 75475, Paris, France."
}
},
{
"@type": "Person",
"name": "Sebastien Froelich",
"url": "https://recherchemedicale.com/author/Sebastien%20Froelich",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurosurgery, Hôpital Lariboisière, Paris VII-Diderot University, 2 rue Ambroise Pare, 75475, Paris, France."
}
},
{
"@type": "Person",
"name": "Yael Sofer",
"url": "https://recherchemedicale.com/author/Yael%20Sofer",
"affiliation": {
"@type": "Organization",
"name": "Institute of Endocrinology, Metabolism, Diabetes and Hypertension, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel."
}
},
{
"@type": "Person",
"name": "Iris Yaish",
"url": "https://recherchemedicale.com/author/Iris%20Yaish",
"affiliation": {
"@type": "Organization",
"name": "Institute of Endocrinology, Metabolism, Diabetes and Hypertension, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel."
}
},
{
"@type": "Person",
"name": "Karen Tordjman",
"url": "https://recherchemedicale.com/author/Karen%20Tordjman",
"affiliation": {
"@type": "Organization",
"name": "Institute of Endocrinology, Metabolism, Diabetes and Hypertension, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Metabolic and Dietary Factors in Acne Vulgaris and Evaluation of the Acne Vulgaris Treatment with Oral Contraceptive-Based Therapies in Young Adult Women.",
"datePublished": "2023-03-20",
"url": "https://recherchemedicale.com/article/36986218",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/nu15061488"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adverse effects of gender-affirming hormonal therapy in transgender persons: Assessing reports in the French pharmacovigilance database.",
"datePublished": "2022-06-06",
"url": "https://recherchemedicale.com/article/35653182",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/fcp.12806"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sublingual Estradiol Offers No Apparent Advantage Over Combined Oral Estradiol and Cyproterone Acetate for Gender-Affirming Hormone Therapy of Treatment-Naive Trans Women: Results of a Prospective Pilot Study.",
"datePublished": "2023-12-13",
"url": "https://recherchemedicale.com/article/38130980",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1089/trgh.2023.0022"
}
},
{
"@type": "ScholarlyArticle",
"name": "Gender confirmation hormonal treatment use in young Polish transgender binary and non-binary persons.",
"datePublished": "2022-12-15",
"url": "https://recherchemedicale.com/article/36519648",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5603/EP.a2022.0088"
}
},
{
"@type": "ScholarlyArticle",
"name": "Risk of intracranial meningioma with three potent progestogens: A population-based case-control study.",
"datePublished": "2022-06-20",
"url": "https://recherchemedicale.com/article/35621369",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.15423"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Recherchemedicale.com",
"item": "https://recherchemedicale.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés polycycliques",
"item": "https://recherchemedicale.com/mesh/D011083"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés à cycles fusionnés",
"item": "https://recherchemedicale.com/mesh/D000072473"
},
{
"@type": "ListItem",
"position": 4,
"name": "Stéroïdes",
"item": "https://recherchemedicale.com/mesh/D013256"
},
{
"@type": "ListItem",
"position": 5,
"name": "Stéroïdes chlorés",
"item": "https://recherchemedicale.com/mesh/D013258"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cyprotérone",
"item": "https://recherchemedicale.com/mesh/D003534"
},
{
"@type": "ListItem",
"position": 7,
"name": "Acétate de cyprotérone",
"item": "https://recherchemedicale.com/mesh/D017373"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Acétate de cyprotérone - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Acétate de cyprotérone",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-02-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Acétate de cyprotérone",
"description": "Comment diagnostiquer un excès d'androgènes ?\nQuels symptômes indiquent un besoin d'acétate de cyprotérone ?\nQuels tests sont nécessaires avant traitement ?\nL'acétate de cyprotérone est-il utilisé pour les hommes ?\nComment évaluer l'efficacité du traitement ?",
"url": "https://recherchemedicale.com/mesh/D017373?page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Acétate de cyprotérone",
"description": "Quels sont les effets secondaires courants ?\nL'acétate de cyprotérone cause-t-il des changements de poids ?\nPeut-il provoquer des troubles menstruels ?\nQuels signes d'allergie peuvent apparaître ?\nL'acétate de cyprotérone affecte-t-il la libido ?",
"url": "https://recherchemedicale.com/mesh/D017373?page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Acétate de cyprotérone",
"description": "Comment prévenir l'hirsutisme ?\nY a-t-il des mesures préventives pour les effets secondaires ?\nPeut-on éviter les troubles menstruels ?\nQuels conseils diététiques peuvent aider ?\nL'exercice physique aide-t-il à prévenir les symptômes ?",
"url": "https://recherchemedicale.com/mesh/D017373?page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Acétate de cyprotérone",
"description": "Comment l'acétate de cyprotérone est-il administré ?\nQuelle est la posologie standard pour l'hirsutisme ?\nCombien de temps faut-il pour voir des résultats ?\nPeut-on combiner ce traitement avec d'autres médicaments ?\nY a-t-il des alternatives à l'acétate de cyprotérone ?",
"url": "https://recherchemedicale.com/mesh/D017373?page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Acétate de cyprotérone",
"description": "Quelles complications peuvent survenir avec le traitement ?\nL'acétate de cyprotérone augmente-t-il le risque de cancer ?\nComment gérer les effets indésirables graves ?\nY a-t-il des risques pour la santé mentale ?\nQuels signes indiquent une réaction allergique grave ?",
"url": "https://recherchemedicale.com/mesh/D017373?page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Acétate de cyprotérone",
"description": "Quels facteurs augmentent le risque d'hirsutisme ?\nLe surpoids est-il un facteur de risque ?\nLes troubles hormonaux sont-ils héréditaires ?\nLe stress influence-t-il les niveaux d'androgènes ?\nLes médicaments peuvent-ils affecter les niveaux hormonaux ?",
"url": "https://recherchemedicale.com/mesh/D017373?page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un excès d'androgènes ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic se fait par des tests sanguins mesurant les niveaux d'androgènes."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un besoin d'acétate de cyprotérone ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent l'hirsutisme, l'acné sévère et des irrégularités menstruelles."
}
},
{
"@type": "Question",
"name": "Quels tests sont nécessaires avant traitement ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests hormonaux et un examen clinique sont nécessaires pour évaluer l'état."
}
},
{
"@type": "Question",
"name": "L'acétate de cyprotérone est-il utilisé pour les hommes ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est utilisé pour traiter des conditions comme l'hypersexualité et l'acné."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité du traitement ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par l'amélioration des symptômes et des tests hormonaux."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent fatigue, nausées, et changements d'humeur."
}
},
{
"@type": "Question",
"name": "L'acétate de cyprotérone cause-t-il des changements de poids ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent éprouver une prise ou une perte de poids."
}
},
{
"@type": "Question",
"name": "Peut-il provoquer des troubles menstruels ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut entraîner des irrégularités menstruelles chez certaines femmes."
}
},
{
"@type": "Question",
"name": "Quels signes d'allergie peuvent apparaître ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent indiquer une allergie."
}
},
{
"@type": "Question",
"name": "L'acétate de cyprotérone affecte-t-il la libido ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut réduire la libido chez certains patients en raison de ses effets anti-androgènes."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hirsutisme ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi hormonal régulier et un mode de vie sain peuvent aider à prévenir l'hirsutisme."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour les effets secondaires ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et une communication ouverte avec le médecin sont essentiels."
}
},
{
"@type": "Question",
"name": "Peut-on éviter les troubles menstruels ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un ajustement de la posologie et un suivi régulier peuvent aider à éviter ces troubles."
}
},
{
"@type": "Question",
"name": "Quels conseils diététiques peuvent aider ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et riche en fibres peut aider à réguler les hormones."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à prévenir les symptômes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut aider à réguler les niveaux hormonaux et à réduire les symptômes."
}
},
{
"@type": "Question",
"name": "Comment l'acétate de cyprotérone est-il administré ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est généralement administré par voie orale sous forme de comprimés."
}
},
{
"@type": "Question",
"name": "Quelle est la posologie standard pour l'hirsutisme ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie standard est souvent de 50 à 100 mg par jour, selon la gravité."
}
},
{
"@type": "Question",
"name": "Combien de temps faut-il pour voir des résultats ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les résultats peuvent être visibles après 3 à 6 mois de traitement continu."
}
},
{
"@type": "Question",
"name": "Peut-on combiner ce traitement avec d'autres médicaments ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être combiné avec d'autres traitements hormonaux ou contraceptifs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des alternatives à l'acétate de cyprotérone ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, d'autres anti-androgènes comme la spironolactone peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le traitement ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des troubles hépatiques ou des thromboses peuvent survenir."
}
},
{
"@type": "Question",
"name": "L'acétate de cyprotérone augmente-t-il le risque de cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent un risque accru de certains cancers hormonodépendants avec usage prolongé."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets indésirables graves ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est crucial de consulter un médecin immédiatement en cas d'effets indésirables graves."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques pour la santé mentale ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements d'humeur et des troubles dépressifs peuvent survenir chez certains patients."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une réaction allergique grave ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme un gonflement du visage, des difficultés respiratoires nécessitent une attention immédiate."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'hirsutisme ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme des antécédents familiaux et des troubles endocriniens augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le surpoids est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le surpoids peut exacerber les symptômes d'hirsutisme et d'autres troubles hormonaux."
}
},
{
"@type": "Question",
"name": "Les troubles hormonaux sont-ils héréditaires ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains troubles hormonaux peuvent avoir une composante héréditaire dans les familles."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il les niveaux d'androgènes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut augmenter les niveaux d'androgènes et aggraver les symptômes."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils affecter les niveaux hormonaux ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent interférer avec les niveaux hormonaux et provoquer des effets indésirables."
}
}
]
}
]
}
The etiopathogenesis of acne is complex, as several endo- and exogenous factors that affect the sebaceous-hair unit are involved in the development of acne lesions. The main aim of the study was to ev...
Limited data are available on adverse drug reactions (ADRs) of gender-affirming hormone therapy (HT), mainly due to the lack of population-based studies with adequate controls, thus making spontaneous...
Chronic gender-affirming hormone therapy (GAHT) with sublingual estradiol (SLE) has not been studied. We aimed to compare GAHT with SLE only, to combined oral (CO) estradiol and cyproterone acetate, i...
Twenty-two trans women enrolled into either the CO arm or the SLE-only arm (0.5 mg four times daily) in this 6-month prospective study. Anthropometric and laboratory variables were collected at baseli...
Subjects in the SLE were older, 26.3±5.8 years versus 20.1±2.3 years,...
Both treatments achieved similar clinical changes. At this stage, SLE, which repeatedly induces alarming excursions of serum estradiol throughout the day, appears to offer no advantage over the CO app...
Gender confirmation hormonal treatment (GCHT) is a cornerstone of medical treatments for persistent gender dysphoria, which is expected and required by many transgender binary and non-binary individua...
A total of 166 adult transgender participants answered our online questionnaire between November 2020 and December 2021. The population was divided into 2 groups: assigned male at birth (AMB, n = 37) ...
Most patients (91.9% AMB and 92.2% AFB) did not use gender confirmation medical treatments before the age of 18 years. The most common medication used for GCHT before the age of 18 was cyproterone ace...
These treatments (including pubertal blocking) seem to be rarely commenced in Poland before the age of 18 years. In adults, treatment consists mostly of either testosterone or oestradiol, and cyproter...
A dose-dependent association between the use of cyproterone acetate (CPA) and intracranial meningioma has been identified but data for other potent progestogens are scarce. The association was assesse...
In this nationwide population-based case-control study, cases underwent surgery for intracranial meningioma in France from 2009 to 2018. They were matched to five control subjects for sex, year of bir...
In total, 25,216 cases were included (75% women, median age 58 years). Progestogen exposure was noted for 9.9% of cases (2497/25,216) and 1.9% (2382/126,080) of controls, with an odds ratio (OR) of 6....
A strong association between prolonged exposure to potent progestogens and surgery for meningioma was observed. The risk increased from CMA to NOMAC to CPA. Individuals should be informed of this risk...
Numerous studies have confirmed a strong association between progestins and meningiomas and the regression and/or stabilization of meningiomas after discontinuation of treatment. Osteomeningiomas repr...
Thirty-six patients (mean age 49.5 years) who presented with at least one progestin-related osteomeningioma (48 tumors total) were identified from a prospectively collected database of patients and ha...
For half of the 36 patients, treatment was prescribed for signs of hyperandrogenism, such as hirsutism, alopecia, or acne. Most lesions were spheno-orbital (35.4%) or frontal (31.2%). Although the tis...
These results show that while the soft intracranial part of progestin-related osteomeningioma tumor is the most likely to regress after treatment discontinuation, the bony part is more likely to incre...
Follistatin is a glycoprotein that represses members of the transforming growth factor-β superfamily including activin. Higher follistatin levels have been associated with an increased risk for type 2...
Circulating follistatin, endocrine-metabolic markers and hepato-visceral fat were measured longitudinally in 72 girls with PCOS [age, 16 years; body mass index (BMI), 23 Kg/m...
Pre-treatment follistatin levels were similar in PCOS and controls. OCs raised serum follistatin after 6 months (6.8-fold vs 2.5-fold for EE-CA and EE-LNG, respectively). Neither SPIOMET nor PioFluMet...
In girls with PCOS, follistatin levels rise significantly after 6 months on OCs and this increase associates to a worsening of markers of insulin resistance and to changes in liver fat....
Self-prescribed gender-affirming hormone therapy (GAHT) is common practice among transgender women, especially in resource-limited countries, yet the effectiveness of each GAHT regimen to achieve fema...
To describe the use and sex hormone concentrations of various GAHT regimens among transgender women who self prescribe in Thailand....
This was a retrospective study in a community-based setting. Five hundred and 27 records of transgender women taking GAHT who were receiving care at a community health center between January 1, 2018, ...
Blood total testosterone and estradiol concentration after at least a 6-month period of GAHT....
Multiple GAHT regimens were identified including oral estradiol valerate (EV), transdermal 17β-estradiol gel, injectable EV with hydroxyprogesterone caproate, injectable estradiol benzoate with proges...
The inadequate sex hormone levels found in these commonly self-prescribed GAHT regimens provide information regarding the efficacy and safety of GAHT regimens for health care providers working with tr...
This study reflected a real-world situation and provided hormonal profiles among transgender women taking self-prescribed GAHT. However, issues in recall, medical literacy, and adherence to the medica...
Combined hormonal contraceptive pill was a commonly used GAHT regimen in Thai transgender women who self prescribe GAHT. However, this regimen was not effective to decrease testosterone concentrations...
In order to assess the risk of hypertension development, we performed a retrospective analysis of the clinical records of consecutive transgender patients who began gender-affirming hormonal therapy i...
The number of individuals who sexually offended, and who are continued to be treated with pharmacological agents to reduce sex drive after their release from prison or forensic psychiatry, are not kno...
To assess prescription patterns as well as adherence to pharmacological treatment in outpatient clinics in Germany for individuals who have sexually offended and were released from prison or forensic ...
A self-constructed online survey assessing the pharmacological treatment modalities was sent by e-mail to n = 103 forensic outpatient clinics in Germany. Thirty-three (32.0%) completed the questionnai...
Prevalence of the use of different pharmacological agents in the treatment of individuals convicted for sexual offenses as well as the number of patients who have discontinued testosterone-lowering me...
Among all institutions, 22.4% (n = 187) of individuals received pharmacological treatment, with 40.1% receiving gonadotropin-releasing-hormone-agonists, 26.2% antipsychotics, 24.6% selective serotonin...
Substantial regional differences indicate uncertainties regarding the prescription of pharmacological agents for outpatients who have committed sexual offences in Germany. The discontinuiation of TLM ...
The present survey captures prevalences of the pharmacotherapy in forensic aftercare facilities for individuals who have offended sexually, and is the first to record the number of discontinuations. T...
Even though the number of treated individuals has increased in prisons, the majority of pharmacological treatment is still provided by forensic hospitals, which then translates into the outpatient set...